COMPOSICION FARMACEUTICA QUE COMPRENDE ORLISTAT 60MG Y ROSUVASTATINA CALCICA EQUIVALENTE A 5MG DE ROSUVASTATINA EN UNA SOLA UNIDAD DE DOSIS, UTIL PARA EL TRATAMIENTO DE LA OBESIDAD Y LA DISLIPIDEMIA.

摘要

The present invention concerns the pharmaceutical industry, and more specifically the pharmaceutical industry involved in manufacturing products for controlling excess weight and obesity. Specifically, it refers to a pharmaceutical composition for oral administration, which comprises a combination of a hydrogenated derivative of lipstatin or pharmacologically acceptable salts thereof and a HMG-CoA reductase inhibitor for the treatment of obesity and dyslipidaemia. The quantitative composition of this medicament would be Orlistat 60 mg and Rosuvastatin calcium equivalent to 10 mg of Rosuvastatin in a single dosage unit. The advantage of this medicament with respect to those of the prior art lies in the synergistic effect which has the effect of the combination, which achieves the same effect by lowering the dose and therefore has extremely diminished side effects.